Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunity Persistence of Sinovac 23-valent PPV
NCT04989465Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2021
- Primary completion
- Sep 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Sinovac 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Sinovac Biotech Ltd.. Started Sep 2021; status: completed.
02
Drugs
Sinovac 23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04989465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989465.